These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 20416032)
21. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. Shastri M; Alla L; Sabaratnam M J Psychopharmacol; 2006 Nov; 20(6):863-7. PubMed ID: 16891339 [TBL] [Abstract][Full Text] [Related]
22. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Zoldan J; Friedberg G; Weizman A; Melamed E Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178 [No Abstract] [Full Text] [Related]
23. Aripiprazole in chronic schizophrenia: experiences in daily practice. Fernald DS; van Dellen RT; Hovens JE; Loonen AJ Acta Psychiatr Scand; 2006 Oct; 114(4):294; author reply 294. PubMed ID: 16968370 [No Abstract] [Full Text] [Related]
26. Aripiprazole associated with severe exacerbation of Parkinson's disease. Wickremaratchi M; Morris HR; Ali IM Mov Disord; 2006 Sep; 21(9):1538-9. PubMed ID: 16817207 [No Abstract] [Full Text] [Related]
27. Aripiprazole: effectiveness and safety under naturalistic conditions. Di Lorenzo R; Amoretti A; Forghieri M; Fiorini F; Genedani S; Rigatelli M Exp Clin Psychopharmacol; 2007 Dec; 15(6):569-75. PubMed ID: 18179310 [TBL] [Abstract][Full Text] [Related]
28. Aripiprazole: novelty, adherence and understatement. Fear C Int J Neuropsychopharmacol; 2005 Mar; 8(1):131. PubMed ID: 15469664 [No Abstract] [Full Text] [Related]
32. Successful use of aripiprazole for delusional disorder with comorbid pituitary microadenoma: a case report. Jayaram N; Rao NP; Venkatasubramanian G; Behere RV; Varambally S; Gangadhar BN Psychosomatics; 2011; 52(4):395-7. PubMed ID: 21777728 [No Abstract] [Full Text] [Related]
33. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Friedman JH; Berman RM; Goetz CG; Factor SA; Ondo WG; Wojcieszek J; Carson WH; Marcus RN Mov Disord; 2006 Dec; 21(12):2078-81. PubMed ID: 17013906 [TBL] [Abstract][Full Text] [Related]
34. [Aripiprazole-induced parkinsonism in a 64-year-old female patient diagnosed with bipolar disorder]. De Schutter P; Bouckaert F; Peuskens J Tijdschr Psychiatr; 2011; 53(5):299-303. PubMed ID: 21538299 [TBL] [Abstract][Full Text] [Related]
35. Clozapine augmentation with aripiprazole for negative symptoms. Clarke LA; Lindenmayer JP; Kaushik S J Clin Psychiatry; 2006 Apr; 67(4):675-6. PubMed ID: 16669737 [No Abstract] [Full Text] [Related]
36. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. Anghelescu I; Wolf J J Clin Psychiatry; 2004 Sep; 65(9):1286-7. PubMed ID: 15367061 [No Abstract] [Full Text] [Related]
38. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease. Duggal HS; Singh I Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304 [No Abstract] [Full Text] [Related]
39. A case of aripiprazole and tardive dyskinesia. Abbasian C; Power P J Psychopharmacol; 2009 Mar; 23(2):214-5. PubMed ID: 18515468 [TBL] [Abstract][Full Text] [Related]
40. Aripiprazole (Abilify) for schizophrenia. Med Lett Drugs Ther; 2003 Feb; 45(1150):15-6. PubMed ID: 12592215 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]